RenovoRx, Inc. (RNXT) stock
Close on Nov 11, 2026Market cap $55.06MP/E –Yield –
RenovoRx, Inc. reported revenue of $2.78M for the twelve months to Sep 30, 2026. Free cash flow was -$12.23M. At the latest close the market valued the company at $55.06M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $55.06M
- P/E ratio
- –
- Price to sales
- 19.83
- Price to book
- 5.93
- Dividend yield
- –
- Free cash flow yield
- -22.20%
Fundamentals
- Revenue
- $2.78M
- Net income
- -$13.02M
- EPS, diluted
- -$0.31
- Free cash flow
- -$12.23M
- Book value per share
- $0.19
- Diluted shares
- 48M
Trading
- Next earnings
- Mar 29, 2027 (estimated, after the close)
- Previous close
- $1.18
- Open
- $1.15
- Day's range
- $1.12 – $1.26
- Volume
- 257,521
- Average volume (20 days)
- 391,859
- Beta (5 years)
- 1.30
- 52-week range
- $0.70 – $2.59
- RSI (14 days)
- 44.1
- Volatility (1 year)
- 85.2%
- Relative volume
- 0.39×
- WACC
- 11.4%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | RNXT | S&P 500 | Difference | RNXT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -4.7% | -2.4% | −2.3 pts | ||
| 3 months | +6.1% | -1.2% | +7.2 pts | ||
| Year to date | +45.2% | +12.3% | +32.9 pts | ||
| 1 year | +14.0% | +12.4% | +1.6 pts | ||
| 3 years | +13.0% | +78.8% | −65.8 pts | +4.1% | +21.4% |
| 5 years | -85.6% | +75.2% | −160.8 pts | -32.2% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases RenovoRx filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Results
- Results
- News
About RenovoRx
Surgical & Medical Instruments & Apparatus
RenovoRx, Inc. is a commercial-stage life sciences company that develops targeted oncology therapies and commercializes local drug-delivery medical devices. The company's core offering centers on its patented Trans-Arterial Micro-Perfusion therapy platform, enabled by its FDA-cleared RenovoCath catheter. This device delivers chemotherapeutic agents across arterial walls directly into solid tumors to bathe target tissue and minimize systemic toxicity. RenovoRx also investigates drug-device combination candidates, including intra-arterial gemcitabine delivery for locally advanced pancreatic cancer and bile duct cancer. Its primary customers include cancer treatment centers, hospitals, and high-volume National Cancer Institute-designated institutions.
Company profile, executives and historyRenovoRx stock: common questions
What is RenovoRx's stock price?
RNXT closed at $1.22 on Nov 11, 2026, up 3.39% on the day. Over the past 52 weeks it traded between $0.70 and $2.59.
What is RenovoRx's market cap?
RenovoRx was worth $55.06M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is RNXT's P/E ratio?
RenovoRx lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.31), so it has no meaningful P/E ratio.
How much revenue does RenovoRx make?
RenovoRx reported revenue of $2.78M for the twelve months to Sep 30, 2026.
Does RenovoRx pay a dividend?
No. RenovoRx has not paid a cash dividend over the last twelve months.
When does RenovoRx report earnings next?
RenovoRx is expected to report Q4 FY2026 results on Mar 29, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has RNXT stock performed over the past year?
Including dividends, RNXT returned +14.0% over the past year, against +12.4% for the S&P 500.
How many RNXT shares are sold short?
1M shares were sold short at the latest FINRA report, 2.35% of the float, or 3.5 days of average trading volume.
Who are RenovoRx's competitors?
Companies most similar to RenovoRx by business, industry and size include CNSY, ICU, PLSE, OSRH, ICCM.
See a number that looks wrong?